FGF23: A Protein with Potential Applications in Cancer and Insulin Sensitivity

Target Name: FGF23

NCBI ID: G8074

FGF23

FGF23: A Protein with Potential Applications in Cancer and Insulin Sensitivity

FGF23 is a protein that is expressed in various tissues throughout the body, including the liver, pancreas, and muscle. It is a key regulator of cell growth and differentiation, and is involved in the development and maintenance of tissues such as hair, nails, and bones. FGF23 has also been shown to play a role in the regulation of inflammation and metabolism.

Despite its importance, little is known about FGF23 beyond its expression and some limited research on its functions. However, there is interest in using FGF23 as a drug target or biomarker, due to its potential role in the treatment of various diseases. In this article , we will explore the biology and potential applications of FGF23.

Phosphatonin and FGF23

Phosphatonins are a family of proteins that play a key role in intracellular signaling. They are involved in regulating various cellular processes, including cell growth, differentiation, and metabolism. FGF23 is a phosphatonin that has been shown to participate in these processes.

One of the key functions of FGF23 is its role in cell proliferation. FGF23 has been shown to stimulate the growth of various types of cells, including muscles, bones, and skin. It does this by promoting the production of the protein SMAD (S/ N-伪-Avalin), which is involved in the regulation of cell growth.

FGF23 has also been shown to regulate cell differentiation. It has been shown to promote the production of the protein ALDH1 (aldehyde dehydrogenase 1), which is involved in the regulation of cell differentiation. This suggests that FGF23 may have a role in the development and maintenance of tissues.

In addition to its role in cell proliferation and differentiation, FGF23 has also been shown to be involved in the regulation of inflammation and metabolism. It has been shown to promote the production of pro-inflammatory cytokines, such as TNF-伪 (transforming growth factor -伪), which are involved in the regulation of inflammation.

FGF23 and diseases

There is interest in using FGF23 as a drug target or biomarker due to its potential role in the treatment of various diseases. One of the main targets for FGF23 is the regulation of cancer growth. FGF23 has been shown to promote the growth of various types of cancer cells, including breast, lung, and ovarian cancer cells.

In addition to its role in cancer growth, FGF23 may also be involved in the regulation of other diseases. For example, it has been shown to be involved in the regulation of insulin sensitivity, which is important for the treatment of type 2 diabetes.

FGF23 as a drug target

FGF23 has been shown to be involved in the regulation of various cellular processes, including cell growth, differentiation, and metabolism. This makes it an attractive target for drug development.

One of the main drugs being developed to target FGF23 is a protein called PD-L1. PD-L1 is a protein that is produced by the immune system and has been shown to promote the growth of various types of cancer cells. By inhibiting the activity of PD-L1, researchers hope to reduce the growth of cancer cells.

Another drug that is being developed to target FGF23 is a protein called JNJ-752655. JNJ-752655 is a small molecule that is designed to inhibit the activity of FGF23. Preclinical studies have shown that JNJ-752655 is effective in inhibiting the growth of various types of cancer cells.

FGF23 as a biomarker

FGF23 may also be used as a biomarker for some diseases. For example, it has been shown to be involved in the regulation of insulin sensitivity, which is an important

Protein Name: Fibroblast Growth Factor 23

Functions: Regulator of phosphate homeostasis (PubMed:11062477). Inhibits renal tubular phosphate transport by reducing SLC34A1 levels (PubMed:11409890). Up-regulates EGR1 expression in the presence of KL (By similarity). Acts directly on the parathyroid to decrease PTH secretion (By similarity). Regulator of vitamin-D metabolism (PubMed:15040831). Negatively regulates osteoblast differentiation and matrix mineralization (PubMed:18282132)

The "FGF23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FGF23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets